The Cytochrome b 245 Heavy Chain pipeline drugs market research report outlays comprehensive information on the Cytochrome b 245 Heavy Chain targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Cytochrome b 245 Heavy Chain pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Genetic Disorders, Cardiovascular, Central Nervous System, and Infectious Disease which include the indications Chronic Granulomatous Disease, Cardiovascular Disease, Pulmonary Hypertension, Alzheimer’s Disease, Epilepsy, and Influenzavirus A Infections. It also reviews key players involved in Cytochrome b 245 Heavy Chain targeted therapeutics development with respective active and dormant or discontinued products.
The Cytochrome b 245 Heavy Chain pipeline targets constitutes close to six molecules. Out of which, approximately three molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase I, IND/ CTA Filed, and Preclinical stages are 1, 1, and 1 respectively. Similarly, the universities portfolio in IND/ CTA Filed, Preclinical, and Discovery comprises 1, 1, and 1 molecule.
Cytochrome b 245 Heavy Chain overview
Cytochrome b 245 Heavy Chain (CYBB) is a crucial component of the phagocyte oxidase (phox) enzyme complex, which is essential to produce reactive oxygen species (ROS) in immune cells. CYBB is primarily expressed in phagocytes, including neutrophils, macrophages, and certain non-phagocytic cells. CYBB is a transmembrane protein located in the phagosomal membrane, and its activation is tightly regulated. Upon stimulation, CYBB undergoes conformational changes and transfers electrons across the membrane, leading to the production of superoxide radicals. These reactive oxygen species contribute to the killing of microbes within the phagosome. Mutations in the CYBB gene can result in chronic granulomatous disease (CGD), a rare genetic disorder characterized by recurrent bacterial and fungal infections.
For a complete picture of Cytochrome b 245 Heavy Chain’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
